A Key Milestone for Therapeutic Exosome Production
TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (“NurExone” or the “Company“), a developer of exosome-based therapies for regenerative medicine, is pleased to announce that it has acquired a master cell bank from a U.S. manufacturer for an undisclosed amount (the “Acquisition”). The Acquisition marks a major step in ensuring a stable and scalable supply chain for production of exosome-based therapies for clinical needs and eventual patient treatment.
The master cell bank provides a well-characterized, Good Manufacturing Practices (“GMP”) grade and exclusive source of human bone marrow mesenchymal stem cells (“MSCs”), the foundation for producing exosomes. The acquired master cell bank contains a large volume of high-concentration MSCs at their earliest stage (Passage Zero), ensuring the cells retain their therapeutic potential and remain potent over very long usage in exosome production. These are stored and handled under stringent U.S. Food and Drug Administration (“FDA”) guidelines and GMP, meeting the high-quality standards for clinical use. Exosomes, naturally occurring nanoparticles derived from human MSCs, play a key role in promoting healing and regeneration. This strategic Acquisition positions NurExone to advance revenue-generating opportunities that leverage exosomes both as a therapeutic agent and as a versatile drug delivery system for targeted applications across various indications.